Eupraxia Pharmaceuticals Inc.

EPRX • Biotechnology

Strong market move

EPRX+12.00%

vs. previous close $7.50

$8.40

▲ +0.90 (+12.00%)

Current price

EarningsLatest report: Mar 31, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$476.39M

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0Healthy liquidity · 15.12Weak profitability

Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 12, 2026, 12:00 AM UTCLast profile update: Aug 13, 2026, 12:50 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$8.40

Change12.00%

Shares Out56.71M

Market Cap$476.39M

Enterprise Value$337.25M

52W Range5.04 - 9.32

Beta1.50

P/E-11.21

P/B3.45

P/FCF-14.81

EV/EBITDA-7.41

EV/FCF-10.49

Price$8.40

Change12.00%

Shares Out56.71M

Market Cap$476.39M

Enterprise Value$337.25M

52W Range5.04 - 9.32

Beta1.50

P/E-11.21

P/B3.45

P/FCF-14.81

EV/EBITDA-7.41

EV/FCF-10.49

Earnings Yield-8.92%

FCF Yield-6.75%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.00

Current Ratio15.12

Quick Ratio15.12

Target$17.00

Target Upside102.38%

Target Median$17.00

Target Range17.00 - 17.00

Volume218.62K

Avg Volume297.39K

EPS Surprise-0.01

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

50/100

Price Attractiveness

Cheap or expensive today

73/100

Why this score▼

Manageable debt level · 0Healthy liquidity · 15.12Weak profitability

Analyst view

Analyst sentiment and price target

EPRX

Analyst sentiment

Based on 2 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Price Target

2026-08-13

Low

$17.00

Mean

$17.00

Median

$17.00

High

$17.00

Company Overview

IPO: 4/5/2024

Industry: Biotechnology

P/B i: 3.45

Debt / Equity i: 0.00

Operating Margin: 0.00%

Net Margin: 0.00%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.00

Current Ratio: 15.12

Quick Ratio: 15.12

Status: Good

🧾

No insider activity

No recent insider transactions available.

About the Company

Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Source - link

Peers

AARD GNFT IVA MDWD NAUT NTHI OBIO RNAC SLS TARA

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients

The number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts analyzed (Cohorts 7-9) was reduced from 62% at baseline to 25% from 24 through to 52 weeks post treatment In the same analysis, 23% of patients reported severe odynophagia at baseline; and no patients reported severe odynophagia at the 24 and 52 weeks timepoints The number of patients experiencing moderate to severe dysphagia (difficulty swallowing) in Cohorts 7-9 was reduced from 77% at baseline to 25% at 24 and 52 weeks post treatment At baseline 31% of patients in Cohorts 7-9 had severe dysphagia; no patients had severe dysphagia at 24 and 52 weeks post treatment EP-104GI continues to be well tolerated by patients receiving the drug. There have been over 130 patients treated in RESOLVE with EP-104GI or placebo (more than 2,000 individual injection sites) with no reported treatment-emergent or procedure related Serious Adverse Events (“SAEs”) VANCOUVER, British Columbia, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced positive results from a new analysis of the RESOLVE study examining the effect of EP-104GI on symptom severity, including for the first time an analysis of the effect of EP-104GI on odynophagia (pain when swallowing).

GlobeNewsWire

Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results

New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI

GlobeNewsWire

Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High?

The consensus price target hints at a 145.4% upside potential for Eupraxia Pharmaceuticals Inc. (EPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX - Get Free Report) have received an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have issued a buy recommendation

Defense World

Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth

VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced updates to its executive leadership and operating structure as the Company continues to prepare for its next stage of clinical and commercial development.

GlobeNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-12	-0.22	-0.23	-0.01
2026-03-12	-0.16	-0.37	-0.21
2025-11-04	-0.23	-0.19	0.04
2025-08-12	-0.21	-0.26	-0.05
2025-05-06	-0.19	-0.21	-0.02
2025-03-20	-0.18	-0.21	-0.03
2024-11-07	-0.13072	-0.17	-0.03928
2024-08-07	-0.16938	-0.17	-0.00062
2024-05-08	-0.17039	-0.21	-0.03961
2023-09-30	-0.11041	-0.24737	-0.13696
2023-06-30	-0.27158	-0.35564	-0.08406
2023-03-31	-0.17006	-0.22852	-0.05846